AR113816A1 - Variantes e isoformas de anticuerpos con actividad biológica reducida - Google Patents

Variantes e isoformas de anticuerpos con actividad biológica reducida

Info

Publication number
AR113816A1
AR113816A1 ARP180103169A ARP180103169A AR113816A1 AR 113816 A1 AR113816 A1 AR 113816A1 AR P180103169 A ARP180103169 A AR P180103169A AR P180103169 A ARP180103169 A AR P180103169A AR 113816 A1 AR113816 A1 AR 113816A1
Authority
AR
Argentina
Prior art keywords
isoforms
variants
antibodies
biological activity
antibody
Prior art date
Application number
ARP180103169A
Other languages
English (en)
Inventor
Masakazu Fukuda
Satoshi Saitoh
Nobuyuki Tanaka
Yosuke Watanabe
Chifumi Seida
Maki Kuwayama
Kensaku Hosoguchi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR113816A1 publication Critical patent/AR113816A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Variantes e isoformas de anticuerpos que tienen una actividad mimética de FVIII reducida en comparación con el Emicizumab, en donde las variantes de los anticuerpos tienen algunos residuos de aminoácido específicos en la región variable escindidos y faltantes (Variantes con corte de Q-CDR), y las isoformas de anticuerpo tienen puentes disulfuro entre las cadenas pesadas que son menos susceptibles a la reducción bajo condiciones reductoras suaves (Isoformas de Disulfuros Protegidos).
ARP180103169A 2017-11-01 2018-10-31 Variantes e isoformas de anticuerpos con actividad biológica reducida AR113816A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017212179 2017-11-01

Publications (1)

Publication Number Publication Date
AR113816A1 true AR113816A1 (es) 2020-06-17

Family

ID=66331990

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103169A AR113816A1 (es) 2017-11-01 2018-10-31 Variantes e isoformas de anticuerpos con actividad biológica reducida

Country Status (19)

Country Link
US (1) US20200283544A1 (es)
EP (1) EP3705496A4 (es)
JP (2) JPWO2019088143A1 (es)
KR (1) KR20200074209A (es)
CN (1) CN111479829A (es)
AR (1) AR113816A1 (es)
AU (1) AU2018361430A1 (es)
BR (1) BR112020008393A2 (es)
CA (1) CA3079053A1 (es)
CL (1) CL2020001113A1 (es)
CR (1) CR20200229A (es)
IL (1) IL274265A (es)
MA (1) MA50534A (es)
MX (1) MX2020003472A (es)
PE (1) PE20210553A1 (es)
SA (1) SA520411871B1 (es)
SG (1) SG11202003833TA (es)
TW (1) TW201930352A (es)
WO (1) WO2019088143A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
KR20180091918A (ko) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
JP7125932B2 (ja) 2016-09-06 2022-08-25 中外製薬株式会社 凝固第ｉｘ因子および／または活性化凝固第ｉｘ因子ならびに凝固第ｘ因子および／または活性化凝固第ｘ因子を認識する二重特異性抗体の使用法
CR20200229A (es) 2017-11-01 2020-07-12 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida
TW202340249A (zh) * 2021-12-22 2023-10-16 日商中外製藥股份有限公司 生物活性降低之抗體變體
CN114544839A (zh) * 2022-01-20 2022-05-27 未名生物医药有限公司 一种抗人神经生长因子抗体的电荷变异体检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US20080075712A1 (en) 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
TW200714313A (en) 2005-04-08 2007-04-16 Chugai Pharmaceutical Co Ltd Antibodies that substitute for coagulation factor VIII
CN101460622A (zh) * 2006-03-31 2009-06-17 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
US9670269B2 (en) * 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
EP2527425A1 (en) * 2006-09-13 2012-11-28 Abbott Laboratories Cell culture improvements
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102099580B1 (ko) * 2010-11-17 2020-04-10 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
WO2012091023A1 (ja) * 2010-12-27 2012-07-05 協和発酵キリン株式会社 培地およびキレート剤を含む水溶液の調製方法
EP2788097A4 (en) 2011-12-07 2015-09-09 Amgen Inc IGG2 DISULFIDE ISOFORMATION SEPARATION
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
JP6962819B2 (ja) * 2015-04-10 2021-11-05 アディマブ， エルエルシー 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
EP3395835B1 (en) * 2015-12-25 2021-02-03 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
CR20200229A (es) 2017-11-01 2020-07-12 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida

Also Published As

Publication number Publication date
US20200283544A1 (en) 2020-09-10
RU2020117440A3 (es) 2022-04-01
SA520411871B1 (ar) 2023-12-19
RU2020117440A (ru) 2021-12-01
CL2020001113A1 (es) 2020-11-20
CR20200229A (es) 2020-07-12
WO2019088143A1 (ja) 2019-05-09
AU2018361430A1 (en) 2020-06-11
SG11202003833TA (en) 2020-05-28
BR112020008393A2 (pt) 2020-11-03
IL274265A (en) 2020-06-30
CN111479829A (zh) 2020-07-31
TW201930352A (zh) 2019-08-01
KR20200074209A (ko) 2020-06-24
EP3705496A1 (en) 2020-09-09
JP2024037761A (ja) 2024-03-19
EP3705496A4 (en) 2021-12-08
PE20210553A1 (es) 2021-03-17
JPWO2019088143A1 (ja) 2020-11-12
MX2020003472A (es) 2020-08-03
CA3079053A1 (en) 2019-05-09
MA50534A (fr) 2020-09-09

Similar Documents

Publication Publication Date Title
CL2020001113A1 (es) Variantes e isoformas de anticuerpos con actividad biológica reducida.
SA517380842B1 (ar) بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام
CO2017007619A2 (es) Anticuerpos humanos contra glicoproteína del virus ébola
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
EA201692476A1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
PE20181338A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
MX2021000156A (es) Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
EA201791775A1 (ru) Цистеиновая протеаза
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
CY1123615T1 (el) Πολυσθενεις και πολυειδικες συντηγμενες πρωτεïνες που δεσμευουν τον dr5
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20141028A1 (es) Nuevos moduladores y metodos para su uso
CU24301B1 (es) Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3)
AR083293A1 (es) Agentes de union a cd33
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
CO2021001544A2 (es) Variantes de anticuerpos anti-cd38 y sus usos
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix
CO2022010337A2 (es) Anticuerpos monoclonales anti-sirpα y usos de los mismos
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
AR090244A1 (es) Formulacion de anticuerpo anti-selectina p
UA118653C2 (uk) Суперагоністи глікопротеїнового гормону тривалої дії
CO2017012397A2 (es) Fragmento de anticuerpo fab anti-ngf humano
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa